| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 04/26/2001 | WO2001029042A1 Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
| 04/26/2001 | WO2001029036A2 Allosteric sites on muscarinic receptors |
| 04/26/2001 | WO2001029028A1 9- (piperazinylalkyl) carbazoles as bax-modulators |
| 04/26/2001 | WO2001029027A1 2-alkoxybenzene derivatives |
| 04/26/2001 | WO2001029026A1 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity |
| 04/26/2001 | WO2001029022A1 Benzopyran derivatives |
| 04/26/2001 | WO2001029015A2 Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists |
| 04/26/2001 | WO2001029012A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 04/26/2001 | WO2001029011A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 04/26/2001 | WO2001029005A1 Bicyclic vasopressin agonists |
| 04/26/2001 | WO2001028586A1 Method of treating fibrosis |
| 04/26/2001 | WO2001028566A1 Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia |
| 04/26/2001 | WO2001005970A3 Gtp-binding protein associated factors |
| 04/26/2001 | WO2000064486A3 Enzymatically activated polymeric drug conjugates |
| 04/26/2001 | WO2000061121A3 Use of molecular weight-amplified hirudin as an anticoagulant in extracorporeal renal replacement therapy |
| 04/26/2001 | WO2000056889A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/26/2001 | WO2000055139A3 Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 04/26/2001 | WO1997035591B1 Method of treating ciliary dyskinesia with uridine triphosphates and related compounds |
| 04/26/2001 | DE19950898A1 New heteroaryl substituted fluoroalkyl-benzoylguanidine derivatives useful for treatment of e.g. ischemias, cardiac infarction, angina, shock, atherosclerosis, cancer and metabolic disorders |
| 04/26/2001 | CA2388497A1 Method of producing differentiated progenitor cells by culturing morula or inner cell mass cells |
| 04/26/2001 | CA2388450A1 Tadg-15: an extracellular serine protease overexpressed in carcinomas |
| 04/26/2001 | CA2388315A1 Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them |
| 04/26/2001 | CA2387886A1 Bicyclic vasopressin agonists |
| 04/26/2001 | CA2386149A1 Allosteric sites on muscarinic receptors |
| 04/26/2001 | CA2385472A1 Isoxazolecarboxamide derivatives |
| 04/25/2001 | EP1094109A2 Human G protein-coupled receptor, PFI-010 |
| 04/25/2001 | EP1094075A1 Human G-protein coupled receptor |
| 04/25/2001 | EP1094063A1 9-(Piperazinylalkyl)carbazoles as Bax-modulators |
| 04/25/2001 | EP1093814A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 04/25/2001 | EP1093457A1 Cytokine receptor common gamma chain like |
| 04/25/2001 | EP1093453A1 Naaladase inhibitors useful as pharmaceutical compounds and compositions |
| 04/25/2001 | CN1292782A Novel unsymmetrically substituted carboxylic acid derivatives, method for producing them, and their use as mixed ETA/ETB-receptor antagonists |
| 04/25/2001 | CN1064954C Orthosubstituted benzoylguanidine, preparation of same, pharmaceutical containing same and application of same |
| 04/24/2001 | US6222016 Amino acid sequence of protein involved in chromosome partitioning; drug screening of bacteriostats and bactericides; antibodies |
| 04/24/2001 | US6221891 Crystal form of N-(4-triflouromethylphenyl)-5-methylisoxazole-4-carboxamide |
| 04/24/2001 | US6221881 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| 04/24/2001 | US6221660 Amino acid sequence; recombinant production; drug screening using membrane preparations |
| 04/24/2001 | US6221627 cDNA clone HDPB130 that encodes a novel human 7-transmembrane receptor |
| 04/24/2001 | CA2053277C Use of lipoxin a4 and its derivatives as antagonists for slow-reacting substances of anaphylaxis |
| 04/19/2001 | WO2001027140A1 Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
| 04/19/2001 | WO2001027113A2 PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES |
| 04/19/2001 | WO2001027107A2 Heterocyclic sodium/proton exchange inhibitors and method |
| 04/19/2001 | WO2001027105A1 Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof |
| 04/19/2001 | WO2001027104A1 Substituted imidazolidinone derivatives |
| 04/19/2001 | WO2001027102A1 Substituted diazepanes |
| 04/19/2001 | WO2001027101A2 Anhydrous salt |
| 04/19/2001 | WO2001027089A1 Pyrimidine derivatives |
| 04/19/2001 | WO2001027081A1 6-position substituted indoline, production and use thereof as a medicament |
| 04/19/2001 | WO2001027070A1 Use of carbonylamino derivatives against cns disorders |
| 04/19/2001 | WO2001027068A1 Biaryl ether derivatives useful as monoamine reuptake inhibitors |
| 04/19/2001 | WO2001026652A1 Fab i inhibitors |
| 04/19/2001 | WO2001026649A1 Use of l-carnitine and its alkanoyl derivatives as osmotic agents in solutions for medical use |
| 04/19/2001 | WO2001001963A8 A method for the improvement of transport across adaptable semi-permeable barriers |
| 04/19/2001 | WO2000068380A3 Extracellular matrix and adhesion-associated proteins |
| 04/19/2001 | WO2000046198A8 Anti-inflammatory indole derivatives |
| 04/19/2001 | WO2000026245A3 Human membrane transport proteins |
| 04/19/2001 | WO2000012720A9 Elongase genes and uses thereof |
| 04/19/2001 | WO1999056785A3 Cell mediated gene delivery using muscle derived cells for treating muscle-and bone-related injury or dysfunction |
| 04/19/2001 | US20010000345 Compounds such as (4,7-dimethylbenzimidazol-5-yl)guanidine; treating nasal congestion, otitis media, asthma, pain, migraine, gastrointestinal disorder, ulcer |
| 04/19/2001 | US20010000344 N-(2-(R)-amino-3-mercaptopropyl)-L-penicillaminyl-1,2,3,4 -tetrahydro-3(S)-isoquinoline carbonyl methionine methylester cyclic disulfide, for example; administering as antitumor agent or to treat restenosis |
| 04/19/2001 | CA2399093A1 Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
| 04/19/2001 | CA2388813A1 Heterocyclic sodium/proton exchange inhibitors and method |
| 04/19/2001 | CA2387535A1 Substituted imidazolidinone derivatives |
| 04/19/2001 | CA2382937A1 Anhydrous salt |
| 04/19/2001 | CA2382605A1 Pyrimidine derivatives |
| 04/18/2001 | EP1092431A2 Lasofoxifene compositions |
| 04/18/2001 | EP1091942A1 Potassium channel blocking agents |
| 04/18/2001 | EP1091757A2 Alpha emitting constructs and uses thereof |
| 04/18/2001 | EP1091736A1 Inhibitors of prenyl-protein transferase |
| 04/18/2001 | EP0771201B1 Use of 2-phenyl-3-aroylbenzothiophenes for the preparation of a medicament for inhibiting primary endometrial hyperplasia |
| 04/18/2001 | CN1291890A 20-Hete antagonists and agonists |
| 04/18/2001 | CN1291486A Medicine for treating prostatic diseases |
| 04/18/2001 | CN1291484A Medicine for treating prostatic diseases |
| 04/18/2001 | CN1064674C Alkoxyaryl compounds, their process of preparation and pharmaceutical compositions which contain them |
| 04/18/2001 | CN1064547C Capsule for treating prostate diseases and preparation process |
| 04/17/2001 | US6218430 Vitamin D3 mimics |
| 04/17/2001 | US6218425 Useful in the treatment of estrogen-related disorders such as osteoporosis, hyperlipidemia, estrogen-related breast cancer, uterine fibrosis, endometriosis, and restenosis |
| 04/17/2001 | US6218418 Therapy of cell proliferative disorders associated with an altered cell dependent kinase activity by administering amino pyrazole derivative to mammal |
| 04/17/2001 | US6218415 Therapy of bone reabsorption by osteoclasts, tumor growth and tumor metastasis, inflammation, cardiovascular disease, nephropathies and retinopathies |
| 04/17/2001 | US6218396 Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia |
| 04/17/2001 | US6218390 Morpholinone and morpholine derivatives and uses thereof |
| 04/17/2001 | US6218385 1,2,4,5-Tetrahydro-benzo[D]azepin derivatives |
| 04/17/2001 | US6218369 Administering flavanolignane selected from silymarin, silybin, silidianin, silicristin, dehydrosilybin, phospholipid complex of one of these flavanolignanes, and mixtures, in combination with antitumor agent |
| 04/17/2001 | US6218159 Amino acid sequence; bacteriostats; bactericides; antibiotics; diagnosis of infections; drug screening |
| 04/17/2001 | US6217859 Orally administering genetic engineered bacteria |
| 04/17/2001 | CA2156742C Phosphonomethyldipeptides |
| 04/12/2001 | WO2001025446A1 Dna encoding prost 07 polypeptide |
| 04/12/2001 | WO2001025434A1 G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
| 04/12/2001 | WO2001025271A2 Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen |
| 04/12/2001 | WO2001025269A2 Human g-protein coupled receptor |
| 04/12/2001 | WO2001025252A1 Tissue plasminogen activator-like protease |
| 04/12/2001 | WO2001025228A1 Amine derivatives |
| 04/12/2001 | WO2001025210A2 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands |
| 04/12/2001 | WO2001025209A1 Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications |
| 04/12/2001 | WO2001025208A1 Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 04/12/2001 | WO2001024783A2 Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence |
| 04/12/2001 | WO2001024628A1 Model animal of mesangial cell proliferative nephritis |
| 04/12/2001 | WO2000056304A3 Anti-inflammatory uses of manzamines |
| 04/12/2001 | DE19947747A1 Treatment of urinary incontinence using (+)-tramadol, O-demethyl-tramadol or O-demethyl-N-mono-desmethyl-tramadol, having strong effect on bladder function without side-effects or analgesic action |
| 04/12/2001 | CA2388487A1 Tissue plasminogen activator-like protease |